JP2021510376A5 - - Google Patents
Info
- Publication number
- JP2021510376A5 JP2021510376A5 JP2020538691A JP2020538691A JP2021510376A5 JP 2021510376 A5 JP2021510376 A5 JP 2021510376A5 JP 2020538691 A JP2020538691 A JP 2020538691A JP 2020538691 A JP2020538691 A JP 2020538691A JP 2021510376 A5 JP2021510376 A5 JP 2021510376A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- cancer
- substituted
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023156385A JP2024001052A (ja) | 2018-01-10 | 2023-09-21 | ベンズアミド化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615857P | 2018-01-10 | 2018-01-10 | |
| US62/615,857 | 2018-01-10 | ||
| PCT/US2019/012695 WO2019139899A1 (en) | 2018-01-10 | 2019-01-08 | Benzamide compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023156385A Division JP2024001052A (ja) | 2018-01-10 | 2023-09-21 | ベンズアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510376A JP2021510376A (ja) | 2021-04-22 |
| JP2021510376A5 true JP2021510376A5 (enExample) | 2022-01-17 |
| JP7355741B2 JP7355741B2 (ja) | 2023-10-03 |
Family
ID=67218673
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538691A Active JP7355741B2 (ja) | 2018-01-10 | 2019-01-08 | ベンズアミド化合物 |
| JP2020538644A Pending JP2021510163A (ja) | 2018-01-10 | 2019-01-08 | ベンズアミド化合物 |
| JP2020538692A Pending JP2021510165A (ja) | 2018-01-10 | 2019-01-08 | ベンズアミド化合物 |
| JP2023156385A Pending JP2024001052A (ja) | 2018-01-10 | 2023-09-21 | ベンズアミド化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538644A Pending JP2021510163A (ja) | 2018-01-10 | 2019-01-08 | ベンズアミド化合物 |
| JP2020538692A Pending JP2021510165A (ja) | 2018-01-10 | 2019-01-08 | ベンズアミド化合物 |
| JP2023156385A Pending JP2024001052A (ja) | 2018-01-10 | 2023-09-21 | ベンズアミド化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US11318134B2 (enExample) |
| EP (4) | EP3737672A4 (enExample) |
| JP (4) | JP7355741B2 (enExample) |
| KR (4) | KR20250008139A (enExample) |
| CN (5) | CN111801320A (enExample) |
| AR (4) | AR114949A1 (enExample) |
| AU (4) | AU2019207608B2 (enExample) |
| BR (2) | BR112020014151A2 (enExample) |
| CA (3) | CA3087262A1 (enExample) |
| ES (1) | ES3013457T3 (enExample) |
| IL (4) | IL316472A (enExample) |
| MX (4) | MX2020007392A (enExample) |
| RU (2) | RU2020120929A (enExample) |
| SG (3) | SG11202005784YA (enExample) |
| TW (5) | TW201934538A (enExample) |
| WO (4) | WO2019139899A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| IL316472A (en) * | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| AU2020310147A1 (en) * | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| EP3972601A4 (en) * | 2019-07-10 | 2023-07-12 | Recurium IP Holdings, LLC | BCL-2 INHIBITOR NANOPARTICLE FORMULATION |
| KR20220100992A (ko) | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
| CA3165472A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| BR112022012283A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| CA3165341A1 (en) * | 2019-12-20 | 2021-06-24 | Ahmed Abdi Samatar | Combinations |
| CN115023229A (zh) * | 2019-12-20 | 2022-09-06 | 里科瑞尔姆Ip控股有限责任公司 | 组合 |
| JP2023515050A (ja) * | 2020-02-21 | 2023-04-12 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | ジフルオロメチルヨード化合物及び方法 |
| CA3173843A1 (en) * | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| AU2021268195A1 (en) * | 2020-05-07 | 2022-09-29 | Recurium Ip Holdings, Llc | Combinations |
| CN116133661A (zh) * | 2020-05-19 | 2023-05-16 | 里科瑞尔姆Ip控股有限责任公司 | 淀粉样变性的治疗 |
| CN115697967B (zh) * | 2020-07-10 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 |
| EP4228645A4 (en) * | 2020-10-16 | 2024-10-23 | Recurium IP Holdings, LLC | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS |
| WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
| CN113143930B (zh) * | 2021-04-08 | 2023-05-30 | 深圳湾实验室 | 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途 |
| CN113816889B (zh) * | 2021-10-11 | 2023-08-22 | 中国药科大学 | 一类4-磺酰亚胺-1H-吡咯类Mcl-1抑制剂及其抗肿瘤医药用途 |
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| JP2003096461A (ja) | 2001-09-25 | 2003-04-03 | Fuji Photo Film Co Ltd | 液晶組成物およびそれを用いた液晶素子 |
| DE10217814A1 (de) | 2002-04-22 | 2003-11-13 | Ibfb Pharma Gmbh | Neue tricyclische Mercaptane, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005079803A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| JP4628140B2 (ja) | 2005-03-03 | 2011-02-09 | 富士フイルム株式会社 | セルロースアシレートフィルム、偏光板および液晶表示装置 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| MX2009002422A (es) | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| AU2007319209B2 (en) | 2006-11-15 | 2012-04-19 | Genentech, Inc. | Arylsulfonamide compounds |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| KR20090087491A (ko) | 2006-12-04 | 2009-08-17 | 아보트 러보러터리즈 | 암 치료요법을 위한 동반 진단 검정 |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| NZ614305A (en) | 2008-12-05 | 2015-03-27 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| EP2442789A1 (en) | 2009-06-18 | 2012-04-25 | Abbott Laboratories | Stable nanoparticulate drug suspension |
| WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| BR112013009531A2 (pt) | 2010-11-11 | 2016-07-19 | Redx Pharma Ltd | derivados de fármaco |
| RU2593231C2 (ru) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| EP2945940B1 (en) | 2013-01-16 | 2020-07-15 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer |
| RS57569B1 (sr) | 2013-03-13 | 2018-10-31 | Abbvie Inc | Postupci za pripremanje agensa koji uzrokuje apoptozu |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9168257B2 (en) | 2013-05-22 | 2015-10-27 | Children's Hospital Medical Center | Combination therapy for MDS |
| AU2014269144B2 (en) | 2013-05-24 | 2019-10-31 | The Cawthron Institute Trust Board | Bioactive compounds |
| CA2917767C (en) | 2013-07-12 | 2022-05-03 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Cystobactamides |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| CN105012318B (zh) | 2014-04-17 | 2020-02-11 | 沈华浩 | 磺酰胺类化合物在气道慢性炎症性疾病中的应用 |
| CN104131034B (zh) | 2014-06-19 | 2017-04-05 | 中山大学 | 一种嵌合载体及其制备方法和应用 |
| WO2016025652A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods |
| CN106999451B (zh) * | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| JP2018508569A (ja) | 2015-02-06 | 2018-03-29 | ユニティ バイオテクノロジー インコーポレイテッド | 老化関連状態の治療における化合物および使用 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| WO2016172194A1 (en) * | 2015-04-20 | 2016-10-27 | Mayo Foundation For Medical Education And Research | Methods and materials for killing hiv infected cells |
| CR20170529A (es) | 2015-05-26 | 2018-01-26 | Hoffmann La Roche | Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2. |
| GB201513481D0 (en) | 2015-07-30 | 2015-09-16 | Univ Manchester | Inhibitor compounds |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN106608895A (zh) | 2015-10-21 | 2017-05-03 | 苏州国匡医药科技有限公司 | 一类具有糖环结构的bcl-2选择性抑制剂及其用途 |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| CN106957315B (zh) | 2016-01-08 | 2019-08-13 | 中国人民解放军第二军医大学 | N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途 |
| AU2017206731A1 (en) | 2016-01-11 | 2018-08-02 | Merrimack Pharmaceuticals, Inc. | Inhibiting B-cell lymphoma 2 (Bcl-2) and related proteins |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| CN106565607B (zh) | 2016-10-11 | 2019-03-26 | 湖北泓肽生物科技有限公司 | 一种l-肌肽的合成方法 |
| CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| CN106749233B (zh) | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| WO2018146506A1 (en) | 2017-02-10 | 2018-08-16 | Universitat Politècnica De València | Therapeutic derivatives |
| CN107089981A (zh) | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| TWI824010B (zh) | 2018-09-18 | 2023-12-01 | 加拿大商聖諾康生命科學公司 | 治療血癌之組合療法 |
-
2019
- 2019-01-08 IL IL316472A patent/IL316472A/en unknown
- 2019-01-08 EP EP19738922.4A patent/EP3737672A4/en not_active Withdrawn
- 2019-01-08 SG SG11202005784YA patent/SG11202005784YA/en unknown
- 2019-01-08 CN CN201980015896.1A patent/CN111801320A/zh active Pending
- 2019-01-08 KR KR1020247043033A patent/KR20250008139A/ko active Pending
- 2019-01-08 CN CN202410225032.5A patent/CN118084905A/zh active Pending
- 2019-01-08 IL IL275762A patent/IL275762B2/en unknown
- 2019-01-08 BR BR112020014151-8A patent/BR112020014151A2/pt not_active Application Discontinuation
- 2019-01-08 CN CN201980015882.XA patent/CN111801327B/zh active Active
- 2019-01-08 AU AU2019207608A patent/AU2019207608B2/en active Active
- 2019-01-08 WO PCT/US2019/012695 patent/WO2019139899A1/en not_active Ceased
- 2019-01-08 KR KR1020207022443A patent/KR20200108298A/ko not_active Withdrawn
- 2019-01-08 MX MX2020007392A patent/MX2020007392A/es unknown
- 2019-01-08 US US16/957,861 patent/US11318134B2/en not_active Ceased
- 2019-01-08 KR KR1020207022537A patent/KR20200108301A/ko not_active Withdrawn
- 2019-01-08 RU RU2020120929A patent/RU2020120929A/ru unknown
- 2019-01-08 BR BR112020014160-7A patent/BR112020014160A2/pt not_active Application Discontinuation
- 2019-01-08 US US16/957,862 patent/US11344546B2/en not_active Expired - Fee Related
- 2019-01-08 WO PCT/US2019/012719 patent/WO2019139907A1/en not_active Ceased
- 2019-01-08 EP EP19738858.0A patent/EP3737681A4/en not_active Withdrawn
- 2019-01-08 CN CN201980015923.5A patent/CN111788203A/zh active Pending
- 2019-01-08 EP EP19738996.8A patent/EP3740487B1/en active Active
- 2019-01-08 MX MX2020007388A patent/MX2020007388A/es unknown
- 2019-01-08 US US16/957,865 patent/US11590126B2/en active Active
- 2019-01-08 JP JP2020538691A patent/JP7355741B2/ja active Active
- 2019-01-08 CA CA3087262A patent/CA3087262A1/en active Pending
- 2019-01-08 US US18/212,692 patent/USRE50643E1/en active Active
- 2019-01-08 CA CA3087263A patent/CA3087263A1/en active Pending
- 2019-01-08 WO PCT/US2019/012699 patent/WO2019139900A1/en not_active Ceased
- 2019-01-08 CA CA3087261A patent/CA3087261A1/en active Pending
- 2019-01-08 WO PCT/US2019/012704 patent/WO2019139902A1/en not_active Ceased
- 2019-01-08 AU AU2019207616A patent/AU2019207616A1/en not_active Abandoned
- 2019-01-08 JP JP2020538644A patent/JP2021510163A/ja active Pending
- 2019-01-08 SG SG11202005985PA patent/SG11202005985PA/en unknown
- 2019-01-08 EP EP25150549.1A patent/EP4556469A1/en not_active Withdrawn
- 2019-01-08 CN CN202410225030.6A patent/CN118084904A/zh active Pending
- 2019-01-08 SG SG11202005785XA patent/SG11202005785XA/en unknown
- 2019-01-08 MX MX2020007014A patent/MX2020007014A/es unknown
- 2019-01-08 JP JP2020538692A patent/JP2021510165A/ja active Pending
- 2019-01-08 KR KR1020207022538A patent/KR102751751B1/ko active Active
- 2019-01-08 AU AU2019207611A patent/AU2019207611A1/en not_active Abandoned
- 2019-01-08 ES ES19738996T patent/ES3013457T3/es active Active
- 2019-01-08 RU RU2020120928A patent/RU2020120928A/ru unknown
- 2019-01-10 TW TW108101046A patent/TW201934538A/zh unknown
- 2019-01-10 AR ARP190100051A patent/AR114949A1/es not_active Application Discontinuation
- 2019-01-10 TW TW113101066A patent/TW202417442A/zh unknown
- 2019-01-10 TW TW108101045A patent/TW201934550A/zh unknown
- 2019-01-10 TW TW108101047A patent/TW201930317A/zh unknown
- 2019-01-10 TW TW108101048A patent/TWI829664B/zh active
- 2019-01-10 AR ARP190100053A patent/AR114998A1/es unknown
- 2019-01-10 AR ARP190100052A patent/AR114950A1/es not_active Application Discontinuation
- 2019-01-10 AR ARP190100050A patent/AR114948A1/es unknown
-
2020
- 2020-06-30 IL IL275761A patent/IL275761A/en unknown
- 2020-06-30 IL IL275763A patent/IL275763A/en unknown
- 2020-07-13 MX MX2023009185A patent/MX2023009185A/es unknown
-
2022
- 2022-03-28 US US17/656,726 patent/US11813259B2/en active Active
-
2023
- 2023-05-26 US US18/202,622 patent/US11813260B1/en active Active
- 2023-09-20 US US18/471,017 patent/US20240180899A1/en not_active Abandoned
- 2023-09-21 JP JP2023156385A patent/JP2024001052A/ja active Pending
-
2024
- 2024-06-06 AU AU2024203833A patent/AU2024203833A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI837478B (zh) | 用於治療ｂｒａｆ相關的疾病和病症之化合物 | |
| IL275762B1 (en) | Derivatives of phenyl-so2-nh-c(=o)-phenyl-piperazine-ch2-1,2-cyclohexane-bicyclo[1.1.1]pentane and pharmaceutical compositions comprising them | |
| CN101678029B (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| JP7307744B2 (ja) | がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体 | |
| TW202136252A (zh) | 化合物及其用途 | |
| TWI594986B (zh) | Antineoplastic agent effect enhancer | |
| WO2020027083A1 (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| UA119150C2 (uk) | СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2 | |
| JP2016523974A5 (enExample) | ||
| CN111643504A (zh) | Akt抑制剂化合物和化疗剂的组合以及使用方法 | |
| JP2021501756A5 (enExample) | ||
| EP2694073B1 (en) | Combinations of akt and mek inhibitors for treating cancer | |
| JP7214632B2 (ja) | ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物 | |
| JP2019511554A (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| KR20190110581A (ko) | 암 치료 | |
| JP2023553532A (ja) | 癌の処置のための併用療法 | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| EP3603638A1 (en) | COMBINATION THERAPY TECHNIQUE FOR Axl INHIBITORY AGENT AND EGFR TYROSINE KINASE INHIBITOR | |
| JP2023509845A (ja) | 金属塩及びその使用 | |
| US20260041669A1 (en) | Solid forms of a cdk inhibitor | |
| CN114173779A (zh) | 对抗ccr4抗体具有抗性的癌症的治疗剂 | |
| JP2020536844A (ja) | キノリンおよびナフチリジンの誘導体および組成物 | |
| EA043826B1 (ru) | Комбинированная терапия для лечения трижды негативного рака молочной железы | |
| EA047636B1 (ru) | Соединения и способы их применения | |
| HK40064173B (en) | Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as combination drug |